Marcelo Bigal

Dr. Bigal is the President and CEO of Ventus Therapeutics and has extensive experience in neurology. He has published over 320 peer-reviewed papers in the field of neurology, as well as five books. He has been recognized by the American Academy of Neurology with the Harold G. Wolff Award for excellence in research in neurology. Dr. Bigal has over 15 years of pharmaceutical experience spanning R&D, medical and scientific affairs. Prior to Ventus, he was CMO and CSO at Teva Pharmaceuticals, leading the team that developed fremanezumab (Ajovy) for several forms of migraine, as well as deutetrabenazine (Austedo) for the treatment of Huntington's disease and Tardive Dyskinesia, as well as other medicines in neurology, psychiatry, pain, and respiratory diseases approved in the US, Canada, and EU. Prior to his work in the pharmaceutical industry, Dr. Bigal was a faculty member at the Albert Einstein College of Medicine, Department of Neurology, as well as the Director of Research at the New England Center for Headache and Director of Research at Montefiore Headache Center.